BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Olivier Delattre, MD, PhD

POSITION TITLE: INSERM Research Director

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
Sorbonne University Pierre and Marie Curie Campus	MD	1990	Medical Degree
Paris Hospitals, Internship		1991	Paediatrics
Paris Diderot University	PhD	1991	Molecular Biology

A. Personal Statement

Olivier Delattre, MD, PhD was trained in pediatric oncology and in genetics. His research area mainly investigates the genetic and biology of pediatric cancers. His laboratory has identified the genetic alterations of a variety of childhood cancers including the EWS-FLI1 rearrangement in Ewing sarcoma, the SMARCB1 inactivation in rhabdoid tumors, the ALK activation mutation in neuroblastoma and the BCOR-CCNB1 fusion in Ewing-like sarcoma. He has also contributed identifying major tumor predisposing mutations or genetic susceptibility factors in neurofibromatosis type II, rhabdoid syndrome predisposition, neuroblastoma and Ewing sarcoma. His lab has also strong interest in deciphering the cellular origin of pediatric cancers and particularly Ewing sarcoma, neuroblastoma and rhabdoid tumors and in finding new therapeutic targets in these diseases. Olivier Delattre is a member of EMBO since 2011 and of Academia Europea since 2012.
Olivier Delattre is Director of the Cancer, Heterogeneity, Instability and Plasticity department Inserm U830 and Director of the SIREDO center, a pediatric center that gathers researchers and physicians in the oncopaediatrics, adolescent and young adult fields to bring new medications to patients as quickly as possible.

B. Positions, Scientific Appointments, and Honors

Positions and Employment:

1981-1991;	Medical internship in Paris Hospitals, specialist in Paediatrics
1982-1984	National military period, Department of Paediatrics, Principal Hospital, Dakar (Senegal)
1986-1987	Laboratory of Molecular Genetics of Eucaryotes, Pr Pierre Chambon, Strasbourg (team R. Breathnach)
1991	INSERM Recruitment as Researcher
1994	Research Director, INSERM
1999-2006	Director INSERM/ Institut Curie U 509, Molecular Pathology of Cancer
2007-2019	Director INSERM/ Institute Curie U 830, Genetic and Biology of cancer
2009-2011	Deputy Director of the Research Center of Institut Curie
2012-2017	Director of the Integrated Research Site in Cancerology, Institut Curie

Honors and Awards:

1993	Jacques Sylvain Bourdin award of Comité de l'Essonne of the Ligue Nationale contre le Cancer
1993	EURE award of the Ligue Nationale contre le Cancer

1995	Rose Lamarca award of Clinical Investigation of the Fondation our la Recherche Médicale
1995	Olga Sain award of Comité de Paris of the Ligue Nationale Contre le Cancer
1996	Gaston Rousseau award of Académie des Sciences
2000	Award of Académie Nationale de Médecine
2007	EUROCANCER award
2009	Charles Oberling award
2014	Herman suit CTOS Special Award Lecture
2016	ARC Leopold Griffuel award
2022	Grand prix Inserm

C. Contributions to Science

Patent PCT/EP2020/079832
IMMUNOTHERAPY TARGETING TUMOR NEOANTIGENIC PEPTIDES

Publications > 400
Citations > 35 000
H-index (Web of Science) 97
10 major publications (selection)

- Vibert, J., Saulnier, O., Collin, C., Petit, F., Borgman, K.J.E., Vigneau, J., Gautier, M., Zaidi, S., Pierron, G., Watson, S., Gruel, N., Hénon, C., Postel-Vinay, S., Deloger, M., Raynal, V., Baulande, S., Laud-Duval, K., Hill, V., Grossetête, S., Dingli, F., Loew, D., Torrejon, J., Ayrault, O., Orth, M.F., Grünewald, T.G.P., Surdez, D., Coulon, A., Waterfall, J.J., and Delattre, O. Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions. Mol Cell S1097-2765(22)00382-3 (2022).

- Didier Surdez, Sakina Zaidi, Sandrine Grossetête, Karine Laud-Duval, Anna Sole Ferre, Lieke Mous, Thomas Vourc'h, Franck Tirode, Gaelle Pierron, Virginie Raynal, Sylvain Baulande, Erika Brunet, Véronique Hill, Olivier Delattre. STAG2 mutations alter CTCF-anchored 1 loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma. *Cancer Cell*, 39, 810-828 (2021)

- Gruenewald, T.G.P., Bernard, V., Gilardi-Hebenstreit, P., Raynal, V., Surdez, D., Aynaud, M.-M., Mirabeau, O., Cidre-Aranaz, F., Tirode, F., Zaidi, S., Perot, G., Jonker, A.H., Lucchesi, C., Le Deley, M.-C., Oberlin, O., Marec-Berard, P., Veron, A.S., Reynaud, S., Lapouble, E., Boeva, V., Frio, T.R., Alonso, J., Bhatia, S., Pierron, G., Cancel-Tassin, G., Cussenot, O., Cox, D.G., Morton, L.M., Machiela, M.J., Chanock, S.J., Charnay, P., and Delattre, O. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. *Nat Genet*. 47, 1073-+ (2015)

- Tirode, F., Surdez, D., Ma, X., Parker, M., Le Deley, M.C., Bahrami, A., Zhang, Z., Lapouble, E., Grossetete-Lalami, S., Rusch, M., Reynaud, S., Rio-Frio, T., Hedlund, E., Wu, G., Chen, X., Pierron, G., Oberlin, O., Zaidi, S., Lemmon, G., Gupta, P., Vadodaria, B., Easton, J., Gut, M., Ding, L., Mardis, E.R., Wilson, R.K., Shurtleff, S., Laurence, V., Michon, J., Marec-Berard, P., Gut, I., Downing, J., Dyer, M., Zhang, J., and Delattre, O. Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. *Cancer Discov*. 4, 1342–1353 (2014)

- Postel-Vinay, S., Véron, A.S., Tirode, F., Pierron, G., Reynaud, S., Kovar, H., Oberlin, O., Lapouble, E., Ballet, S., Lucchesi, C., Kontny, U., González-Neira, A., Picci, P., Alonso, J., Patino-Garcia, A., de Paillerets, B.B., Laud, K., Dina, C., Froguel, P., Clavel-Chapelon, F., Doz, F., Michon, J., Chanock, S.J., Thomas, G., Cox, D.G., and Delattre, O. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. *Nat. Genet*. 44, 323–327 (2012).

- Pierron, G., Tirode, F., Lucchesi, C., Reynaud, S., Ballet, S., Cohen-Gogo, S., Perrin, V., Coindre, J.-M., and Delattre, O. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. *Nat. Genet*. 44, 461–466 (2012)

- Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., Valteau-Couanet, D., Frebourg, T., Michon, J., Lyonnet, S., Amiel, J., and Delattre, O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. *Nature* 455, 967–970 (2008)

- Tirode, F., Laud-Duval, K., Prieur, A., Delorme, B., Charbord, P., and Delattre, O. Mesenchymal stem cell features of Ewing tumors. *Cancer Cell* 11, 421–429 (2007)

- Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck, M.F., Ambros, P., Handgretinger, R., Aurias, A., and Delattre, O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature* 394, 203–206 (1998)

- Delattre, O., Zucman, J., Melot, T., Garau, X.S., Zucker, J.M., Lenoir, G.M., Ambros, P.F., Sheer, D., Turc-Carel, C., and Triche, T.J. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. *N. Engl. J. Med*. 331, 294–299 (1994)

- Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., and Rouleau, G. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. *Nature* 359, 162–165 (1992)